401 related articles for article (PubMed ID: 26514681)
21. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
Harringer S; Hejl M; Enyedy ÉA; Jakupec MA; Galanski MS; Keppler BK; Dyson PJ; Varbanov HP
Dalton Trans; 2021 Jun; 50(23):8167-8178. PubMed ID: 34031671
[TBL] [Abstract][Full Text] [Related]
22. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
23. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
24. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
Gabano E; Ravera M; Trivero F; Tinello S; Gallina A; Zanellato I; Gariboldi MB; Monti E; Osella D
Dalton Trans; 2018 Jun; 47(25):8268-8282. PubMed ID: 29892758
[TBL] [Abstract][Full Text] [Related]
25. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
Jayawardhana AMDS; Bhandari S; Kaspi-Kaneti AW; Kshetri M; Qiu Z; Cheline M; Shen H; Dunietz BD; Zheng YR
Dalton Trans; 2023 Aug; 52(31):10942-10950. PubMed ID: 37490033
[TBL] [Abstract][Full Text] [Related]
26. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
27. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
28. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
29. Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.
Varbanov HP; Jakupec MA; Roller A; Jensen F; Galanski MS; Keppler BK
J Med Chem; 2013 Jan; 56(1):330-44. PubMed ID: 23214999
[TBL] [Abstract][Full Text] [Related]
30. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
Najjar A; Rajabi N; Karaman R
Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
[TBL] [Abstract][Full Text] [Related]
31. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy.
Xiao H; Song H; Zhang Y; Qi R; Wang R; Xie Z; Huang Y; Li Y; Wu Y; Jing X
Biomaterials; 2012 Nov; 33(33):8657-69. PubMed ID: 22938766
[TBL] [Abstract][Full Text] [Related]
32. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
[TBL] [Abstract][Full Text] [Related]
33. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
34. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
[TBL] [Abstract][Full Text] [Related]
35. Anticancer platinum (IV) prodrugs with novel modes of activity.
Chin CF; Wong DY; Jothibasu R; Ang WH
Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
[TBL] [Abstract][Full Text] [Related]
36. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
[TBL] [Abstract][Full Text] [Related]
37. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
38. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
Liu W; Chen X; Xie M; Lou L; Ye Q; Yu Y; Hou S
J Inorg Biochem; 2008 Oct; 102(10):1942-6. PubMed ID: 18707762
[TBL] [Abstract][Full Text] [Related]
40. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]